Paul Kaye

Accepting PhD Students

Paul is a member of the Experimental Medicine and Biomedicine research group at Hull York Medical School.

A randomized, double-blind phase 2b trial to evaluate efficacy of ChAd63-KH for treatment of post kala-azar dermal leishmaniasis
Kaye, P., 12 Sept 2024, In: Molecular Therapy: Methods and Clinical development. 32, 3, 11 p., 101310.
Research output: Contribution to journal › Article › peer-review

Open Access
File
Distinct lung cell signatures define the temporal evolution of diffuse alveolar damage in fatal COVID-19
Milross, L., Hunter, B., McDonald, D., Merces, G., Thomson, A., Hilkens, C. M. U., Wills, J., Rees, P., Jiwa, K., Cooper, N., Majo, J., Ashwin, H., Duncan, C. J. A., Kaye, P. M., Bayraktar, O. A., Filby, A. & Fisher, A. J., Jan 2024, In: EBioMedicine. 99, 15 p., 104945.
Research output: Contribution to journal › Article › peer-review

Open Access
File
Early reduction in PD-L1 expression predicts faster treatment response in human cutaneous leishmaniasis: Correction
Dey, N. S., Senaratne, S., Somaratne, V., Madarasinghe, N. P., Seneviratne, B., Forrester, S., Montes de Oca, M., Reis, L. C., Moulik, S., Walrad, P. B., Chatterjee, M., Goto, H., Wickremasinghe, R., Lagos, D., Kaye, P. M. & Ranasinghe, S., 1 Mar 2024, In: Journal of Clinical Investigation. 134, 5, 1 p., e180162.
Research output: Contribution to journal › Article

Open Access

Paul Kaye, PhD FRCPath FMedSci